Literature DB >> 3484513

Heterogeneity of clones from a human metastatic melanoma detected by autologous cytotoxic T lymphocyte clones.

A Anichini, G Fossati, G Parmiani.   

Abstract

The possibility that a single human tumor may be composed of an heterogeneous population of cells with respect to susceptibility to lysis by autologous CTL clones was investigated by testing six cytolytic clones derived by micromanipulation against the autologous metastatic melanoma, Me28, and against 31 clones derived from Me28 by cloning in soft agar. Highly significant differences in the lysis of many tumor clones were observed by three of the CTL effectors in comparison with the cytotoxicity achieved on Me28. These results indicate that cloned cellular reagents can detect heterogeneity among cells isolated from the same melanoma, and suggest that the target determinants recognized on the autologous tumor might be differentially expressed on different neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484513      PMCID: PMC2188019          DOI: 10.1084/jem.163.1.215

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  13 in total

1.  HLA-DC antigens can serve as recognition elements for human cytotoxic T lymphocytes.

Authors:  H Spits; J Borst; M Giphart; J Coligan; C Terhorst; J E De Vries
Journal:  Eur J Immunol       Date:  1984-04       Impact factor: 5.532

2.  Distinct forms of both alpha and beta subunits are present in the human Ia molecular pool.

Authors:  R S Accolla; N Gross; S Carrel; G Corte
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

3.  Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens.

Authors:  P G Natali; A Bigotti; R Cavaliere; M R Nicotra; S Ferrone
Journal:  J Natl Cancer Inst       Date:  1984-07       Impact factor: 13.506

4.  Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens.

Authors:  P G Natali; M Viora; M R Nicotra; P Giacomini; A Bigotti; S Ferrone
Journal:  J Natl Cancer Inst       Date:  1983-09       Impact factor: 13.506

5.  Adoptive immunotherapy of cancer: accomplishments and prospects.

Authors:  S A Rosenberg
Journal:  Cancer Treat Rep       Date:  1984-01

6.  Detection of a novel human class II HLA antigen.

Authors:  A J Watson; R DeMars; I S Trowbridge; F H Bach
Journal:  Nature       Date:  1983 Jul 28-Aug 3       Impact factor: 49.962

7.  Clonal variation in expression of a human melanoma antigen defined by a monoclonal antibody.

Authors:  M Y Yeh; I Hellström; K E Hellström
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

Review 8.  Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture.

Authors:  L J Old
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

9.  Antigenic heterogeneity of clones and subclones from human melanoma cell lines demonstrated by a panel of monoclonal antibodies and flow microfluorometry analysis.

Authors:  C Cillo; J P Mach; M Schreyer; S Carrel
Journal:  Int J Cancer       Date:  1984-07-15       Impact factor: 7.396

10.  Clonal analysis of cytotoxic T-lymphocyte response to autologous human metastatic melanoma.

Authors:  A Anichini; G Fossati; G Parmiani
Journal:  Int J Cancer       Date:  1985-05-15       Impact factor: 7.396

View more
  9 in total

1.  Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.

Authors:  A Knuth; T Wölfel; E Klehmann; T Boon; K H Meyer zum Büschenfelde
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

Review 2.  Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2-activated lymphocytes (LAK).

Authors:  C Gambacorti-Passerini; L Rivoltini; M Radrizzani; R Supino; M Mariani; G Parmiani
Journal:  Cancer Metastasis Rev       Date:  1988-12       Impact factor: 9.264

3.  Modulation by cytokines of HLA antigens, intercellular adhesion molecule 1 and high molecular weight melanoma associated antigen expression and of immune lysis of clones derived from the melanoma cell line MeM 50-10.

Authors:  M Maio; B Gulwani; S Tombesi; S Ferrone
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  An efficient strategy to induce and maintain in vitro human T cells specific for autologous non-small cell lung carcinoma.

Authors:  Glenda Canderan; Paola Gruarin; Daniela Montagna; Raffaella Fontana; Gabriele Campi; Giulio Melloni; Catia Traversari; Paolo Dellabona; Giulia Casorati
Journal:  PLoS One       Date:  2010-08-09       Impact factor: 3.240

Review 5.  Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.

Authors:  B M Vose
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

6.  Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.

Authors:  P Nisticò; R Mortarini; L B De Monte; A Mazzocchi; M Mariani; F Malavasi; G Parmiani; P G Natali; A Anichini
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

7.  Generation and characterization of two human alpha/beta T cell clones. Recognizing autologous breast tumor cells through an HLA- and TCR/CD3-independent pathway.

Authors:  P Nisticò; P De Berardinis; S Morrone; T Alonzi; C Buono; I Venturo; P G Natali
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

8.  MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens.

Authors:  T S Kim; E P Cohen
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

Review 9.  Human autologous tumor-specific T cells in malignant melanoma.

Authors:  C D Platsoucas
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.